These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 13791535)

  • 1. Erythrocyte glycolysis in erythroblastotic newborns. Erythrocyte glycolysis also in Rh-positive red cells coated with anti-D antibodies.
    ABRAHAMOV A; DIAMOND LK
    AMA J Dis Child; 1960 Feb; 99():202-5. PubMed ID: 13791535
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro studies of red cell fragility in anti-D hemolytic disease of the newborn.
    GREENWALT TJ; TRIANTAPHYLLOPOULOS DC
    J Lab Clin Med; 1955 Jan; 45(1):135-40. PubMed ID: 13233638
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies.
    Markham KB; Rossi KQ; Nagaraja HN; O'Shaughnessy RW
    Am J Obstet Gynecol; 2015 Jul; 213(1):68.e1-68.e5. PubMed ID: 25644438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the in vitro behaviour of erythrocytes coated with Rh antibodies.
    SJOLIN S
    Acta Soc Med Ups; 1955 Dec; 60(5-6):224-34. PubMed ID: 13301990
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistence of maternal anti-Rh (anti-D) in an Rh-positive infant.
    NORRIS HJ; YUNIS E
    J Lancet; 1963 Jun; 83():243-4. PubMed ID: 13938968
    [No Abstract]   [Full Text] [Related]  

  • 6. [Successful emergency treatment of a case with severe hemolytic disease of the newborn due to maternal Rh deletion phenotype-D].
    Liu KL; Li BJ; Peng JY
    Zhonghua Er Ke Za Zhi; 2006 Jun; 44(6):473-4. PubMed ID: 16836866
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunohematologic observations of erythroblastotic infants. II. The quantitative and qualitative nature of the Rh antibody.
    STURGEON P
    Am J Clin Pathol; 1954 Feb; 24(2):115-25. PubMed ID: 13124279
    [No Abstract]   [Full Text] [Related]  

  • 8. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
    Kumpel BM
    Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemolytic disease due to antibodies other than anti-D.
    LEVINE P
    Rev Hematol; 1955; 10(2):215-26; discussion, 256-64. PubMed ID: 13255416
    [No Abstract]   [Full Text] [Related]  

  • 10. Consumption of anti-D in the erythroblastotic fetus.
    Gottvall T; Selbing A
    Acta Obstet Gynecol Scand; 1998 May; 77(5):500-3. PubMed ID: 9654170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The half-life of passively acquired antibody globulin molecules in infants.
    WIENER AS
    J Exp Med; 1951 Sep; 94(3):213-21. PubMed ID: 14861379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Need to clarify the cause of hemolysis in case report of newborn with clinically significant hemolytic disease and passive transfer of anti-D from maternal RhIG.
    Watchko JF; Triulzi D
    Transfusion; 2014 Nov; 54(11):3017-8. PubMed ID: 25385405
    [No Abstract]   [Full Text] [Related]  

  • 13. [Metabolic aspects of the initial stages of erythrocyte destruction in hemolytic disease of the newborn].
    Dobronravov AV; Novitskaia AV; Voznesenskiĭ NK
    Vopr Okhr Materin Det; 1975 Jun; 20(6):30-7. PubMed ID: 1169854
    [No Abstract]   [Full Text] [Related]  

  • 14. Presence of anti-C but no anti-D in a cde/cde mother giving birth to a CDe/cde baby.
    HEISTO H; KORNSTAD L
    Vox Sang; 1961 May; 6():298-303. PubMed ID: 13713025
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of Rh immune globulin: a review.
    Sutton GP; Jay A; Lim YS; Noland JE; Boral LI
    Indiana Med; 1988 Apr; 81(4):321-2. PubMed ID: 2834434
    [No Abstract]   [Full Text] [Related]  

  • 16. Oxygen capacity and affinity of blood from erythroblastotic newborns. I. Effects of plasma environment on erythrocytes containing fetal or adult hemoglobin.
    ABRAHAMOV A; SMITH CA
    AMA J Dis Child; 1959 Apr; 97(4):375-9. PubMed ID: 13636691
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of feto-maternal red cell allo-immunizations].
    Bricca P; Guinchard E; Guitton Bliem C
    Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Specificity and incidence of erythrocyte antibodies in pregnant patients with intrauterine transfusions for fetal erythroblastosis].
    Hoch H; Giers G; Bald R; Hanfland P
    Beitr Infusionsther; 1992; 30():439-42. PubMed ID: 1284755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion support in the management of immune haemolytic disorders.
    Plapp FV; Beck ML
    Clin Haematol; 1984 Feb; 13(1):167-83. PubMed ID: 6327130
    [No Abstract]   [Full Text] [Related]  

  • 20. Is the recommended minimum dose of anti-D adequate considering the rise in obesity?
    Regan FA; Naftalin J; Springer V; Paterson-Brown S
    Transfus Med; 2008 Aug; 18(4):266-8. PubMed ID: 18783586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.